{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:35:29Z","timestamp":1778272529360,"version":"3.51.4"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0195316","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T14:21:06Z","timestamp":1522765266000},"page":"e0195316","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":62,"title":["A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro"],"prefix":"10.1371","volume":"13","author":[{"given":"Takehisa","family":"Kawata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Murai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nami","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waka","family":"Haruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youji","family":"Shoukei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Hisada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Yanagida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihito","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"J Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"F Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/1744-9987.12030","article-title":"Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients","volume":"17","author":"M Taniguchi","year":"2013","journal-title":"Ther Apher Dial"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0735-1097(01)01781-8","article-title":"Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?","volume":"39","author":"P Raggi","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ki.2013.279","article-title":"High rates of death and hospitalization follow bone fracture among hemodialysis patients","volume":"85","author":"F Tentori","year":"2014","journal-title":"Kidney Int"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"EF Nemeth","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00774-006-0687-y","article-title":"Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels","volume":"24","author":"T Kawata","year":"2006","journal-title":"J Bone Miner Metab"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.pharmthera.2005.06.019","article-title":"Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism","volume":"109","author":"N Nagano","year":"2006","journal-title":"Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfm534","article-title":"Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients","volume":"23","author":"M Fukagawa","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2215\/CJN.07050714","article-title":"A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM)","volume":"10","author":"JB Wetmore","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.2215\/CJN.11501210","article-title":"Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns","volume":"6","author":"T Akizawa","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2215\/CJN.13081211","article-title":"Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study","volume":"7","author":"M Fukagawa","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/kisup.2013.91","article-title":"Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan","volume":"3","author":"S Fukuma","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"J Cunningham","year":"2005","journal-title":"Kidney Int"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"P Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"GM Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/1744-9987.12352","article-title":"Evaluation of Parathyroidectomy for Secondary and Tertiary Hyperparathyroidism by the Parathyroid Surgeons' Society of Japan","volume":"20","author":"Y Tominaga","year":"2016","journal-title":"Ther Apher Dial"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","article-title":"Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials","volume":"10","author":"SC Palmer","year":"2013","journal-title":"PLoS Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"GA Block","year":"2004","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1542-4758.2009.00397.x","article-title":"Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients","volume":"14","author":"Y Gincherman","year":"2010","journal-title":"Hemodial Int"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4009\/jsdt.43.309","article-title":"The mechanism of upper-gastrointestinal complication after taking cinacalcet hydrochloride","volume":"43","author":"K Fukumoto","year":"2010","journal-title":"Nihon Toseki Igakkai Zasshi"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00003088-200746060-00003","article-title":"Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole","volume":"46","author":"RZ Harris","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1177\/0091270007304103","article-title":"Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies","volume":"47","author":"D Nakashima","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1517\/13543776.2011.568479","article-title":"Novel calcium sensing receptor ligands: a patent survey","volume":"21","author":"L Kiefer","year":"2011","journal-title":"Expert Opin Ther Pat"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.3748\/wjg.v12.i33.5363","article-title":"In vitro and in vivo effects of ferulic acid on gastrointestinal motility: inhibition of cisplatin-induced delay in gastric emptying in rats","volume":"12","author":"OA Badary","year":"2006","journal-title":"World J Gastroenterol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/jpet.114.214155","article-title":"GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species","volume":"350","author":"AR Rutter","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial","volume":"317","author":"GA Block","year":"2017","journal-title":"JAMA"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14656566.2017.1303482","article-title":"Etelcalcetide for the treatment of secondary hyperparathyroidism","volume":"18","author":"N Hamano","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1191\/1078155205jp154oa","article-title":"A reporting system for the assessment of chemotherapy toxicity","volume":"11","author":"G Sassi","year":"2005","journal-title":"J Oncol Pharm Pract"},{"key":"ref30","first-page":"106","article-title":"Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management","volume":"25","author":"S Boussios","year":"2012","journal-title":"Ann Gastroenterol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride","volume":"48","author":"D Padhi","year":"2009","journal-title":"Clin Pharmacokinet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0195316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T17:19:08Z","timestamp":1588958348000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0195316"}},"subtitle":[],"editor":[{"given":"Dengshun","family":"Miao","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0195316","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732973509.793577514","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]}}}